Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Coukos and colleagues conduct a phase 1 study to evaluate the benefit of adoptive transfer of ex vivo-expanded, vaccine-primed T cells in patients with ovarian cancer—a cancer type that often does not respond to immune checkpoint blockade.
Derrien et al. analyze three patients relapsing on talquetamab, a bispecific antibody against CD3 and GPRC5D, and show that acquired resistance is mediated by genetic inactivation or by long-range epigenetic silencing of GPRCD5.
Coorens et. al. perform whole-genome sequencing and phylogenetic analyses in a child patient with leukemia that underwent lineage switch following therapy, finding that the AML arose from a pre-existing clone, rather than the most recent ALL relapse.
Isakoff and colleagues demonstrate the safety and feasibility, as well as the clinical efficacy, of neoadjuvant niraparib in a phase II study in patients with HER2-negative and BRCA-altered breast cancer.
Pramesh and colleagues report a study on the risk factors and outcomes in a large cohort of patients with cancer infected with SARS-CoV-2 from a tertiary care cancer center in India.
Italiano and colleagues demonstrate the utility of mature tertiary lymphoid structures to predict response to immunotherapy, with pathologic analysis in three independent patient cohorts spanning multiple tumor types.
Brastianos and colleagues report interim trial results on the intracranial clinical benefit of palbociclib for patients with progressive metastatic brain cancer carrying cyclin-dependent kinase pathway alterations.
Rugge and colleagues report that patients with cancer, particularly those who are older and male, face a significantly increased risk of adverse outcomes of SARS-CoV-2 infection.